PITTSBURGH--(BUSINESS WIRE)--April 1, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Tizanidine Hydrochloride Tablets, 2mg and 4 mg.

Tizanidine Hydrochloride is the generic version of Elan Corporation's Zanaflex^®, which is a short-acting drug indicated for the management of spasticity.

Mylan will manufacture this product in its Morgantown, West Virginia facility.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com.

    CONTACT: Mylan Laboratories Inc., Pittsburgh
             Kris King, 412/232-0100

    SOURCE: Mylan Laboratories Inc.